GCP
IMRX icon

GSA Capital Partners’s Immuneering IMRX Stock Holding History

GSA Capital Partners’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$404K Buy
+76,752
New +$393K 0.03% 1052
2025
Q4 		– Sell
-37,836
Closed -$265K – 1860
2025
Q3 		$265K Buy
+37,836
New +$196K 0.02% 1271
2023
Q1 		– Sell
-23,371
Closed -$113K – 1683
2022
Q4 		$113K Sell
23,371
-9,739
-29% -$86.3K 0.01% 1290
2022
Q3 		$474K Buy
+33,110
New +$263K 0.06% 608

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's IMRX Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Immuneering (IMRX) in Q1 2026: 76,752 shares worth $404K. The stake represents 0.03% of the portfolio and ranks #1052 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in IMRX as recently as Q3 2025.

GSA Capital Partners first reported a position in IMRX in Q3 2022 and has held it in 4 quarters since. The position peaked at $474K in Q3 2022. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • GSA Capital Partners held 76,752 shares of Immuneering worth $404K as of Q1 2026.
  • Immuneering was a new GSA Capital Partners position in Q1 2026.
  • Immuneering made up 0.03% of GSA Capital Partners's portfolio in Q1 2026, its #1052 holding.
  • GSA Capital Partners first reported a position in Immuneering in Q3 2022 and has held it in 4 quarters since.
  • GSA Capital Partners's Immuneering position peaked at $474K in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.